Collaboration

Image of the earth showing the UK and Scandinavia
#Cancer Research UK #Collaboration #Norwegian Cancer Society #Oncology

UK-Norway partnership to speed up cancer drug discovery

Cancer Research UK and the Norwegian Cancer Society (NCS) have announced a new multi-project strategic partnership to maximise the unique drug development capabilities of both countries. Under the partnership, NCS intends to share funding and expertise to accelerate the development of cancer drug candidates with the… Read More

#Cancer Research #News

#AI / data analytics / healthtech / informatics #Clinical trial design #Collaboration #Exonate #Exploristics #Ophthalmology

Partners enhance trial design using cloud-based simulation

Exploristics and Exonate have announced the completion of a successful collaboration to optimise the study design for Exonate’s upcoming Phase IIb study for diabetic eye disease. The collaboration has supported ongoing development of Exonate’s lead candidate, EXN407, following a recent successful Phase Ib/IIa study in November. Read More

#News

Team of scientists working in a lab
#Biotech #Collaboration #Contract Research Organisations (CROs) #Drug discovery #Torx Software

Webinar: Biotech experts share their tips for effective collaboration

Join DDW and Cresset for this free event ‘Enhancing collaboration in drug discovery – a biotech perspective’. The event will take place on 28 March at 2pm GMT / 3pm CET / 9am EST / 6am PST. Delivery of synthesis targets… Read More

#News

#Artificial intelligence (AI) #Collaboration #Drug discovery #Elsevier #Iktos #Partnership

Elsevier and Iktos launch AI-powered drug discovery database

Elsevier and Iktos have partnered to strengthen Elsevier's chemistry solution, Reaxys, by combining the company’s chemistry data with synthetic planning AI technologies developed by Iktos. The partnership aims to support R&D organisations to decrease the time required to complete Design-Make-Test-Analyse cycles of small molecules, thus reducing the length and cost… Read More

#Business & Investment #News

#Collaboration #Fibrocor Therapeutics #Monoclonal antibodies #Phase I trial

New R&D collaboration to advance Alport Syndrome programme

Fibrocor Therapeutics has entered into a research and development (R&D) collaboration with the McQuade Center for Strategic Research and Development (MSRD) to advance its Alport Syndrome programme. The agreement includes a single digit million US$ upfront payment and additional funding that has the potential to cover the cost of studies… Read More

#Business & Investment #News

Team of scientists in the lab
#Biotech #Collaboration #Contract Research Organisations (CROs) #Drug discovery #Torx Software

Webinar: How to collaborate effectively across multiple teams

Join DDW and Cresset for this free event ‘Enhancing collaboration in drug discovery – a biotech perspective’. The event will take place on 28 March at 2pm GMT / 3pm CET / 9am EST / 6am PST. Delivery of synthesis targets… Read More

#News

A team working in a laboratory
#Biotech #Collaboration #Contract Research Organisations (CROs) #Drug discovery #Torx Software

Enhancing collaboration in drug discovery: Register now

Join DDW and Cresset for this free event ‘Enhancing collaboration in drug discovery – a biotech perspective’. The event will take place on 28 March at 2pm GMT / 3pm CET / 9am EST / 6am PST. Delivery of synthesis targets… Read More

#News

A team working in a laboratory
#Biotech #Collaboration #Drug discovery #Lab technology #Torx Software #Webinar

Enhancing collaboration in drug discovery – a biotech perspective

Delivery of synthesis targets within small molecule drug discovery often involves many chemists and other collaborators, both internal and external, across multiple locations. Harnessing skills and knowledge from distributed teams can create challenges for efficiently managing the ideation process and prioritisation, assignment and delivery of agreed targets. Read More

Webinar date:
Brought to you by Cresset
#Webinars

#Astellas Pharma #CAR-T #Cell therapy #Collaboration #Immuno-oncology #In vivo #Kelonia Therapeutics #Xyphos Biosciences

Companies agree $800m deal for in vivo CAR-T cell therapy

Astellas-owned Xyphos Biosciences and Kelonia Therapeutics have entered into a research collaboration and license agreement to develop novel immuno-oncology therapeutics. Under the terms of the agreement, the companies plan to combine Kelonia’s iGPS with Xyphos’ ACCEL technology to develop in vivo CAR-T cell therapies targeting up to two programmes. Kevin… Read More

#Business & Investment #News #Trending News

#Collaboration #Dermatology #Finance #Funding #Immuno-dermatology #Medicxi

$100M financing to advance immuno-dermatology pipeline 

Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi. The company originates from the aggregation of six Medicxi companies.  Co-founded by Medicxi and several dermatology and scientific experts, including John Harris (UMass Chan Medical School), Brian Kim (Icahn School… Read More

#Business & Investment #News

European map
#Advanced Therapies Europe #Biologics / Biotechnology #Cancer immunotherapy #CAR-T #Cell and gene therapy #Cell therapy #Collaboration #Europe #Immuno-oncology #Market reporting #Oncology #Start-ups

New podcast: Why is Europe a drug discovery epicentre?

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: European drug discovery and development success stories,… Read More

#News

#Business #Collaboration #Partnership

Six collaborations driving drug discovery innovation

1. Amgen and NVIDIA Amgen has announced plans to advance drug discovery using NVIDIA’s DGX SuperPOD-powered insights from human datasets. The NVIDIA DGX SuperPOD will be installed at Amgen’s deCODE genetics’ headquarters in Reykjavik, Iceland and will be used to build a human diversity atlas for drug target and disease-specific… Read More

#Business & Investment #News

T cell attacking cancer cell
#AbbVie #CAR-T #Collaboration #Haematology #In vivo #Umoja Biopharma

Collaboration boosts development of novel in-situ CAR-T cell therapies

AbbVie and Umoja Biopharma have entered into two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology. The first agreement provides AbbVie an exclusive option to license Umoja's CD19 directed in-situ generated CAR-T cell therapy candidates. This includes UB-VV111, Umoja's lead clinical programme… Read More

#Business & Investment #News

#Breast cancer #Collaboration #Mayo Clinic #Oncology #Precision medicine #SimBioSys

US collaboration to advance precision drugs for breast cancer

Techbio SimBioSys and the Mayo Clinic have entered into a strategic collaboration to develop novel digital precision medicine solutions for breast cancer. The aim of the collaboration is to develop cloud-based clinical software tools that will support the end-to-end decision-making process for early-stage breast cancer patients, including drug selection and… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Collaboration #Drug development #Drug discovery #Partnership

Key industry partnerships advancing drug discovery

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis' hereditary angioedema (HAE) drug candidate donidalorsen in Europe. Donidalorsen is an investigational ligand-conjugated antisense (LICA) medicine designed to target the prekallikrein, or PKK,… Read More

#Business & Investment #News

Natural killer cells
#Bispecific Antibodies #Cell therapy #Collaboration #NAYA Biosciences #Oncology #ONK Therapeutics

Partners explore NK cell therapy and bispecific antibodies combo

ONK Therapeutics and NAYA Biosciences have agreed to develop a combination therapy of ONK’s optimally-engineered natural killer (NK) cell therapies and NAYA’s FLEX-NK bispecific antibodies. The partnership will explore the combination of ONK’s ONKT105, CISH + TGFβR2 double knock-out (KO), sIL-15 knock-in (KI) allogeneic NK cell therapy with NAYA’s GPC3-targeted… Read More

#Business & Investment #Cancer Research #News